iiinova — where your digital self keeps evolving

Reposted by Anuraag Jena

Elliot Tapper @ebtapper.bsky.social · 23/12/2024

Early Terli Giving terlipressin at lower creatinines (1.5-2.0) or within 12 hours of presentation (skipping the “albumin challenge”) 1. From the RCTs journals.lww.com/hepcomm/page... 2. Pilot trial doi.org/10.1007/s106... #liversky

journals.lww.com

Image Gallery : Early treatment with terlipressin in patients with hepatorenal syndrome yields improved clinical outcomes in North American studies : Hepatology Communications

2177

Reposted by Anuraag Jena

Beatriz Gros @bealoquebea.bsky.social · 18/12/2024

The QUASAR trial- guselkumab vs placebo in mod-severe UC 1️⃣Induction 200mg IV (0,4,8) or placebo 📗Maintenance 200mg SC q4w, 100mg SC q8w or placebo Guselkumab better than placebo in all the outcomes @thelancet.bsky.social www.thelancet.com/journals/lan...

033

Reposted by Anuraag Jena

Atoosa Rabiee @atoosarabiee.bsky.social · 10/12/2024

It's that time of the year again. In no particular order, I would like to share a few of #livertwitter in 2024 with #liversky These could be original research, guidance statement, position paper or editorial. This is def not an inclusive list. Feel free to add to the 🧵

12617

Reposted by Anuraag Jena

Michael Chiorean @mchiorean4.bsky.social · 09/12/2024

Excellent overview on personalized #IBD therapy for #crohnsdisease complications by @MRegueiroMD at #AIBD2024. Take home point: failure of medical therapy is an adverse event that could be serious!

163

Reposted by Anuraag Jena

Beatriz Gros @bealoquebea.bsky.social · 27/11/2024

🎉The latest IBD-Ell newsletter is out! - New trials added 🌟We've far surpassed 400 summarized trials🌟 - New guidelines - New cheat sheet with lymphocyte trafficking and anti-integrins Thanks for following along! www.ibd-eii.com Subscribe for free anytime 📩 #IBD

22011

Reposted by Anuraag Jena

Malcolm Tan @ibdgastrodocsg.bsky.social · 16/11/2024

Primary sclerosing cholangitis. #LiverSky #IBDSky

183

Reposted by Anuraag Jena

Katrina Ray @heykatray.bsky.social · 20/11/2024

It's my favourite time of year - Year in Review time - and the first batch have landed online in NatRevGastroHep. These short articles summarise the top research in 2024 and key advances in a range of topics @natureportfolio.bsky.social www.nature.com/nrgastro/rev... #GastroSky #Liversky #Microsky

nature.com

Reviews & Analysis | Nature Reviews Gastroenterology & Hepatology

Read the Reviews & Analysis articles from Nature Reviews Gastroenterology & Hepatology

1154

Reposted by Anuraag Jena

Frank I. Scott, MD MSCE @frankiscottmd.bsky.social · 19/11/2024

The AGA’s first-ever living guideline formoderate-to-severe #UlcerativeColitis led by S Singh, @berkeleydoc.bsky.social, @manasiagrawal.bsky.social, @jhaydek.bsky.social , @ashwinmdibd, @EdwardLoftus2 and myself prioritizes early use of advanced txs over a step-up approach. ow.ly/t2Ru50UahEi

ow.ly

DEFINE_ME

1115

Reposted by Anuraag Jena

Malcolm Tan @ibdgastrodocsg.bsky.social · 18/11/2024

Periappendiceal red patch in ulcerative colitis - aka caecal patch, appendiceal orifice inflammation - a curious finding - usually does not influence management - does not mean that the disease is extensive #IBDSky

2122

Reposted by Anuraag Jena

Rob Brierley @robbrierley.bsky.social · 19/11/2024

Vedolizumab to prevent postoperative recurrence of Crohn's disease (the REPREVIO RCT) "Vedolizumab prevented postoperative recurrence of CD & should be considered as a prophylactic treatment in individuals with risk factors for recurrence." www.thelancet.com/journals/lan... #GastroSky #IBDSky

0185

Reposted by Anuraag Jena

Malcolm Tan @ibdgastrodocsg.bsky.social · 17/11/2024

CAVALRY trial: Open-label RCT of Child B/C cirrhosis pts with high risk varices. - combination of carvedilol + banding reduces the risk of bleeding at 12 months - reducing portal pressures + eradicating varices have additive effects without causing harm #LiverSky #MedSky

084

Reposted by Anuraag Jena

Malcolm Tan @ibdgastrodocsg.bsky.social · 17/11/2024

PREDICT-UC Multicenter open-label RCT in acute severe ulcerative colitis. Higher doses of IFX did not result in better clinical response by days 7/14, nor colectomy rates by 3 mths. Maintenance dosing for intensified/accelerated dosing groups limited by local restrictions. #IBDSky

194

Reposted by Anuraag Jena

Elliot Tapper @ebtapper.bsky.social · 15/11/2024

This is the most important resource for people interested in inflammatory bowel disease ibd-eii.com It is run by Beatriz Gros She is not on BlueSky yet. Please peer pressure her

ibd-eii.com

IBD-EII | This platform is intended to help share evidence-based data regarding inflammatory bowel diseases in a summarized way

2146